Side-by-side comparison of AI visibility scores, market position, and capabilities
New York specialty ingredients (NYSE: IFF) at $11.48B 2024 net sales, EBITDA +16%; flavors/fragrances + N&B health/biosciences ($26B 2021 acquisition), 2025 guidance 1-4% growth competing with Givaudan and dsm-firmenich.
International Flavors & Fragrances Inc. (IFF) is a New York City, New York-based global specialty ingredients company — publicly traded on the New York Stock Exchange (NYSE: IFF) as an S&P 500 Materials component — creating and manufacturing flavors, fragrances, enzymes, probiotics, food ingredients, cosmetic actives, and pharmaceutical excipients for consumer goods companies, food manufacturers, beverage companies, and pharmaceutical firms through approximately 20,000 employees in 110 countries. In fiscal year 2024, IFF reported net sales of $11.48 billion and adjusted operating EBITDA growth of 16% to $2.21 billion, demonstrating improved profitability following the challenging integration of the DuPont Nutrition & Biosciences business (acquired 2021 for ~$26 billion in the largest transaction in IFF's history). For 2025, IFF guided 1-4% comparable currency-neutral sales growth, with continued margin improvement as the integration synergies are realized. CEO Jon Erik Fyrwald leads the company through its integration and portfolio optimization phase. IFF operates across four segments: Nourish (flavors, functional ingredients, proteins, food and beverage innovation), Scent (fine fragrances, consumer fragrances, cosmetic actives), Health & Biosciences (enzymes, microbiome, probiotics, animal nutrition), and Pharma Solutions (pharmaceutical excipients and delivery systems) — serving every major category of consumer products from food and beverages to personal care, household products, and medicine.
Richmond VA tobacco and nicotine (NYSE: MO) ~$9.7B net revenue FY2024; Marlboro 40%+ US cigarette share, on! oral pouch competing with Zyn, 50%+ operating margins, ABI stake, competing with Reynolds/BAT.
Altria Group, Inc. is a Richmond, Virginia-based tobacco and nicotine company — publicly traded on the New York Stock Exchange (NYSE: MO) as an S&P 500 Consumer Staples component — manufacturing and selling cigarettes (Marlboro — the best-selling cigarette brand in the United States), smokeless tobacco (Copenhagen, Skoal, Red Seal, Husky chewing tobacco/moist snuff brands), oral nicotine pouches (on! brand), and maintaining a 10.7% ownership stake in Anheuser-Busch InBev (SABMiller acquisition consideration shares) and a 35% stake in JUUL Labs (vaping — original $12.8B investment written down to minimal value following JUUL's regulatory and litigation difficulties) through approximately 5,500 employees. In fiscal year 2024, Altria reported revenues of approximately $20.6 billion (net revenues after excise taxes approximately $9.7 billion), with the cigarette segment (Marlboro generating 40%+ US cigarette market share) contributing the majority of operating income at 50%+ adjusted operating margins — the highest margins in the consumer staples sector reflecting cigarettes' inelastic demand and regulated market structure. CEO Billy Gifford has pivoted Altria's strategy from cigarettes toward smoke-free nicotine products: the on! oral nicotine pouch (acquired full ownership of Helix Innovations in 2023, rebranding as on! to compete with Swedish Match Zyn, the dominant US oral nicotine pouch brand) represents Altria's primary nicotine product diversification vehicle as cigarette volume declines 7-8% annually through consumer quit rates and secular health awareness trends.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.